Although immune checkpoint inhibitors have demonstrated substantial effectiveness in tumors characterized by high microsatellite instability (MSI), and the combination of EGFR/BRAF inhibitors has yielded positive outcomes in CRC) with BRAF V600E mutations, it is important to note that these therapeutic strategies are limited to particular subsets of patients (3–5). The gene discussed is BRAF; the disease is colorectal carcinoma.